InMed Pharmaceuticals (INM) EPS (Weighted Average and Diluted) (2022 - 2026)

InMed Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 5 years, with the latest figure at -$0.69 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 64.43% year-over-year to -$0.69; the trailing twelve-month figure through Mar 2026 stood at -$2.07 (up 82.68% YoY), and the FY2025 full-year result was -$8.36, up 58.49% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.69, down from -$0.51 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was -$0.14 in Q2 2023, with the low at -$15.24 in Q3 2023.
• Historically, EPS (Weighted Average and Diluted) has averaged -$3.32 across 5 years, with a median of -$2.71 in 2024.
• Annual changes were most pronounced in 2024 — EPS (Weighted Average and Diluted) plunged 2562.39% — and 2025, when it jumped 88.25%.
• InMed Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$6.52 in 2022, then soared by 43.1% to -$3.71 in 2023, then climbed by 1.89% to -$3.64 in 2024, then jumped by 85.99% to -$0.51 in 2025, then slumped by 35.29% to -$0.69 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.69 (Q1 2026), -$0.51 (Q4 2025), and -$0.44 (Q3 2025), per Business Quant data.